Overview
Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) . Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others . Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .
Indication
Pain, fever, and inflammation Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures . The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound). Other indications ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include: Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) . Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction . For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) . For the prevention of thromboembolism after hip replacement surgery . For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) . Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site . Important note regarding use of the extended-release formulation In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .
Associated Conditions
- Acute Coronary Syndrome (ACS)
- Anxiety
- Atherothrombotic cerebral infarction
- Cardiovascular Disease (CVD)
- Cardiovascular Events
- Cardiovascular Mortality
- Colorectal Adenomas
- Colorectal Cancer
- Common Cold
- Coronary artery reocclusion
- Death
- Dyspeptic signs and symptoms
- Fever
- Flu caused by Influenza
- Headache
- Heterozygous Familial Hypercholesterolemia (HeFH)
- Inflammation
- Juvenile Idiopathic Arthritis (JIA)
- Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
- Menstrual Pain
- Migraine
- Morbidity
- Mucocutaneous Lymph Node Syndrome
- Muscle Contraction
- Myalgia
- Myocardial Infarction
- Myocardial Infarction (MI), first occurrence
- Neuropathic Pain
- Pain
- Pain caused by Common Cold
- Pain caused by Rheumatism
- Pericarditis
- Polycythemia Vera (PV)
- Pre-Eclampsia
- Rheumatism
- Rheumatoid Arthritis
- Rhino Sinusitis
- Severe Pain
- Spondyloarthropathies
- Stroke
- Systemic Lupus Erythematosus
- Tension Headache
- Thromboembolism
- Thrombosis
- Toothache
- Transient Ischemic Attack
- Vascular Death
- Venous Thromboembolism
- Acute Inflammation
- Articular inflammation
- Atherothrombotic events
- Death caused by Myocardial Infarction
- Fever or influenza-like illness
- Moderate Pain
- Recurrent Ischemic Stroke
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/07/07 | Not Applicable | Not yet recruiting | |||
2025/06/27 | N/A | Not yet recruiting | Shalamar Hospital | ||
2025/05/20 | Phase 3 | Recruiting | The George Washington University Biostatistics Center | ||
2025/05/01 | Phase 3 | Not yet recruiting | FANG HE | ||
2025/04/20 | Phase 2 | Recruiting | |||
2025/02/14 | Phase 1 | Not yet recruiting | |||
2025/01/03 | Phase 4 | Not yet recruiting | |||
2025/01/03 | Phase 4 | Not yet recruiting | Beijing Anzhen Hospital | ||
2024/12/18 | Phase 4 | Recruiting | |||
2024/12/09 | Phase 4 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Physicians Total Care, Inc. | 54868-2094 | ORAL | 325 mg in 1 1 | 8/29/2011 | |
Cabinet Health P.B.C. | 82725-1023 | ORAL | 250 mg in 1 1 | 1/31/2025 | |
Dispensing Solutions, Inc. | 66336-619 | ORAL | 325 mg in 1 1 | 9/1/2011 | |
HF Acquisition Co LLC, DBA HealthFirst | 51662-1494 | ORAL | 325 mg in 1 1 | 5/1/2025 | |
ST. MARY'S MEDICAL PARK PHARMACY | 60760-673 | ORAL | 81 mg in 1 1 | 3/3/2025 | |
Aralez Pharmaceuticals Us Inc. | 70347-081 | ORAL | 81 mg in 1 1 | 9/26/2016 | |
Atland Pharmaceuticals, LLC | 71993-307 | ORAL | 770 mg in 1 1 | 6/19/2023 | |
Sun Pharmaceutical Industries, Inc. | 47335-927 | ORAL | 25 mg in 1 1 | 1/18/2019 | |
Micro Labs Limited | 42571-274 | ORAL | 25 mg in 1 1 | 11/28/2022 | |
Aidarex Pharmaceuticals LLC | 33261-922 | ORAL | 325 mg in 1 1 | 12/26/2013 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
Authorised | 1/9/2020 | ||
Authorised | 1/9/2020 | ||
Authorised | 3/14/2010 | ||
N/A | N/A | N/A |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
ASPIRIN (E.C.) TABLETS 100 mg | SIN05373P | ENTERIC COATED TABLET | 100 mg | 1/29/1991 | |
BOKEY ENTERIC-MICROENCAPSULATED CAPSULES 100 mg | SIN08997P | CAPSULE | 100.00 mg | 11/7/1996 | |
GLYPRIN DISPERSIBLE TABLET | SIN12172P | TABLET | 100 mg | 1/24/2003 | |
CARDIPRIN 100 TABLET 100 mg | SIN05313P | TABLET | 100 mg | 1/8/1991 | |
BAYER ASPIRIN TABLET 500 mg | SIN05362P | TABLET | 500 mg | 1/29/1991 | |
THREE LEGS BRAND MEDICINAL POWDER ASPIRIN 600 mg/sachet | SIN09770P | POWDER | 600 mg/sachet | 5/16/1998 | |
ASPIRIN CARDIO 100 TABLETS 100 mg | SIN08891P | ENTERIC COATED TABLET | 100 mg | 9/4/1996 | |
TRINOMIA HARD CAPSULES 100mg/ 20mg/ 2.5mg | SIN15647P | CAPSULE | 100mg | 3/19/2019 | |
ALKA-SELTZER TABLET (Lemon Flavour) | SIN08632P | TABLET | 324 mg | 4/4/1996 | |
CoPlavix Film-Coated Tablet 75 mg/100 mg | SIN13514P | TABLET, FILM COATED | 100 mg | 8/8/2008 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
Aspirin Chewable Tablets | 国药准字H20217027 | 化学药品 | 片剂 | 4/7/2021 | |
Aspirin Chewable Tablets | 国药准字H20040222 | 化学药品 | 片剂 | 5/7/2020 | |
Aspirin Tablets | 国药准字H62020243 | 化学药品 | 片剂 | 4/10/2020 | |
Aspirin Tablets | 国药准字H64020046 | 化学药品 | 片剂 | 11/21/2019 | |
Aspirin Tablets | 国药准字H37022276 | 化学药品 | 片剂 | 6/15/2023 | |
Aspirin Tablets | 国药准字H42020508 | 化学药品 | 片剂 | 9/3/2020 | |
Aspirin Tablets | 国药准字H34020562 | 化学药品 | 片剂 | 5/12/2020 | |
Aspirin Tablets | 国药准字H12020914 | 化学药品 | 片剂 | 8/27/2020 | |
Aspirin Tablets | 国药准字H41023651 | 化学药品 | 片剂 | 5/6/2020 | |
Aspirin Tablets | 国药准字H53020322 | 化学药品 | 片剂 | 7/31/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
CASPRIN GASTRO-RESISTANT CAPSULES 100MG | N/A | N/A | N/A | 12/9/2024 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
ALKA-SELTZER aspirin 324mg effervescent tablet regular flavour strip (new formula) | 231316 | Medicine | A | 12/3/2014 | |
ASTRIX aspirin 100mg tablet blister pack | 194208 | Medicine | A | 1/30/2012 | |
AMCAL ASPIRIN EC 100 aspirin 100mg enteric coated tablet blister pack (new formulation) | 236225 | Medicine | A | 4/15/2015 | |
ASTRIX 100 Capsules | 30264 | Medicine | A | 10/25/1991 | |
CIPLA LOW DOSE ASPIRIN 100 aspirin 100 mg enteric coated tablet blister pack | 175831 | Medicine | A | 9/15/2010 | |
CHEMISTS' OWN CARDIO ASPIRIN aspirin 100 mg enteric coated tablet blister pack | 462788 | Medicine | A | 9/25/2024 | |
WOOLWORTHS ESSENTIALS ASPIRIN 300 MG uncoated tablet blister pack | 147012 | Medicine | A | 11/6/2007 | |
BLOOMS THE CHEMIST ENTERIC COATED ASPIRIN 100 mg enteric coated tablet blister pack | 258433 | Medicine | A | 8/31/2015 | |
DIPYRAMOLE SR Dipyridamole/Aspirin 200 mg/25 mg modified release capsules bottle | 210816 | Medicine | A | 5/9/2014 | |
ASTRIX aspirin 100mg Capsule Bag | 34057 | Medicine | A | 11/27/1991 |
Help Us Improve
Your feedback helps us provide better drug information and insights.